SYGNIS SA |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.614 PLN | 0.00% |
|
-0.32% | -31.47% |
| 15/05 | Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 14/02 | Sygnis SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2021 | 3.39M 858K 71.63M | Sales 2022 | 28.51M 7.2M 601M | Capitalization | 52.54M 13.28M 1.11B |
|---|---|---|---|---|---|
| Net income 2021 | - 0 0 | Net income 2022 | -2M -505K -42.2M | EV / Sales 2021 | 2.53 x |
| Net cash position 2021 | 3.77M 952K 79.49M | Net Debt 2022 | 2.7M 684K 57.07M | EV / Sales 2022 | 1.94 x |
| P/E ratio 2021 |
118
x | P/E ratio 2022 |
-23.4
x | Employees | 46 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 17.34% |
More Fundamentals
* Assessed data
More news
| 1 week | -0.32% | ||
| 1 month | -9.71% | ||
| 3 months | -37.98% | ||
| 6 months | -35.23% | ||
| Current year | -31.47% |
1 week
0.61
0.62
1 month
0.530.69
Current year
0.521.09
1 year
0.521.66
3 years
0.522.59
5 years
0.183.78
10 years
0.183.78
| Managers | Title | Age | Since |
|---|---|---|---|
Andrzej Burgs
CEO | Chief Executive Officer | - | 01/17/01 |
Olga Czerwinska
CTO | Chief Tech/Sci/R&D Officer | - | 01/18/01 |
Joanna Danaj
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lukasz Kaleta
BRD | Director/Board Member | - | - |
| Director/Board Member | - | - | |
Anastazja Burgs
CHM | Chairman | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/24/04 | 0.614 | 0.00% | 50 |
| 03/24/03 | 0.614 | 0.00% | 100 |
| 31/24/31 | 0.614 | -0.65% | 1,496 |
| 29/24/29 | 0.618 | +0.32% | 50 |
| 28/24/28 | 0.616 | +5.12% | 15,515 |
End-of-day quote Warsaw S.E., June 04, 2024
More quotes
Sygnis SA is a Poland-based company, which egages in Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.
| 1st Jan change | Capi. | |
|---|---|---|
| -31.47% | 3.95M | |
| +46.19% | 56.65B | |
| -6.14% | 39.44B | |
| +39.19% | 39.03B | |
| -6.65% | 26.86B | |
| +12.33% | 26.75B | |
| -21.78% | 19.03B | |
| -0.35% | 12.28B | |
| +24.18% | 12.26B | |
| +28.38% | 12.04B |
- Stock Market
- Equities
- SYG Stock
